Novartis, Aduro: Up-to-$750M Cancer Immunotherapy Collaboration

March 30, 2015 4:58 PM

9 0

Novartis is planning to boost its cancer immunotherapy pipeline with a collaboration with California-based Aduro Biotech worth up to $750 million.

The partnership is focused on the development of cancer immunotherapies based on Aduro’s STING (Stimulator of Interferon Genes) technology, a next-generation method to harness the body’s immune system to fight cancer.

Also read: Boeing seeks U.S. anti-dumping probe against CSeries jet

Read more

To category page